India, Oct. 25 -- Johnson & Johnson (JNJ) announced new data from Cohort 5 of the Phase 1b/2 OrigAMI-4 study showing deep and durable responses with first-line subcutaneous amivantamab and hyaluronidase-lpuj (RYBREVANT FASPRO) combined with a PD-1 inhibitor and fixed-duration carboplatin chemotherapy in patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC).
Among patients with HNSCC excluding human papillomavirus (HPV)-associated oropharyngeal squamous cell carcinoma (OPSCC), the regimen achieved a confirmed overall response rate (ORR) of 77%, including complete responses in 14% of patients. Tumor shrinkage was observed in all evaluable patients, while nearly two-thirds of responses remained ongoing at a media...